论文信息 - 738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial - 字舞流文

738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial

D. O’Malley | A. Redondo | D. Lorusso | A. Auranen | B. Pothuri | A. González Martín | N. Cloven | C. Anderson | S. Abadie-Lacourtoisie | C. Hawkes | E. Braicu | M. Barretina-Ginesta | B. Monk | N. Kebede | S. Han | D. Gupta | D. Chase | A. Amit | R. Shah | T. Woodward